Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| CSTL | 144 | neutral | 4/10 | CEO Derek Maetzold filed a Form 144 on June 1, 2026, to sell 14,008 shares of Castle Biosciences common stock, with an e | Jun 1, 2026 |
| MIRM | 144 | neutral | 3/10 | Christopher Peetz, an officer and director of Mirum Pharmaceuticals, filed a Form 144 notice of intent to sell 30,000 sh | Jun 1, 2026 |
| NGEN | 6-K | bearish | 6/10 | NervGen Pharma priced an underwritten public offering of 24,000,000 common shares and accompanying warrants at $2.50 per | Jun 1, 2026 |
| REVBW | 8-K | neutral | 2/10 | Revelation Biosciences, Inc. filed an 8-K on June 1, 2026, announcing the release of an updated corporate presentation m | Jun 1, 2026 |
| HELP | 6-K | neutral | 2/10 | Helus Pharma (Cybin Inc.) announced its interim CEO will participate in a fireside chat at the Jefferies Global Healthca | Jun 1, 2026 |
| TKNO | 8-K | neutral | 2/10 | Alpha Teknova filed an 8-K reporting that board member Irene Davis will not stand for re-election and will retire at the | Jun 1, 2026 |
| SNSE | CLUSTER | bearish | 7/10 | Two 10% owners of Sensei Biotherapeutics sold a combined $981K in open-market sales at $20/share, representing ~3.5% of | Jun 1, 2026 |
| DARE | DEFA14A | neutral | 4/10 | Dare Bioscience filed a DEFA14A supplement to its proxy statement, disclosing the engagement of Okapi Partners LLC as an | Jun 1, 2026 |
| PCRX | DEFA14A | neutral | 5/10 | Pacira BioSciences issued a press release highlighting that ISS has recommended stockholders vote FOR all three of Pacir | Jun 1, 2026 |
| ZNTL | PRESS-RELEASE | neutral | 2/10 | Zentalis granted 191,000 non-qualified stock options to two newly hired employees as an inducement for employment, with | Jun 1, 2026 |
| OTLK | DEFA14A | bearish | 6/10 | Outlook Therapeutics filed DEFA14A definitive additional proxy materials for its July 16, 2026 Special Meeting. The boar | Jun 1, 2026 |
| TLX | PRESS-RELEASE | bullish | 6/10 | Telix presented Phase 3 ProstACT Global Part 1 safety data at ASCO 2026 for TLX591-Tx in mCRPC, showing acceptable toler | Jun 1, 2026 |
| ISPC | 8-K | bearish | 7/10 | iSpecimen Inc. received a Nasdaq delisting notice on May 29, 2026, for failing to meet the minimum $2.5M stockholders' e | Jun 1, 2026 |
| PCSA | CLUSTER | bullish | 4/10 | Two C-suite insiders at Processa Pharmaceuticals made open-market purchases totaling ~$9K on May 29, 2026, at $2.57/shar | Jun 1, 2026 |
| ELOX | S-1/A | neutral | 5/10 | Eloxx Pharmaceuticals filed an amended S-1 registration statement to offer 1.5 million shares of common stock and pre-fu | Jun 1, 2026 |
| IMRX | 8-K | bullish | 7/10 | Immuneering announced updated Phase 2a data for atebimetinib (IMM-1-104) in first-line pancreatic cancer, showing 17.3-m | Jun 1, 2026 |
| USNA | CLUSTER | neutral | 2/10 | Three USNA insiders, including the CFO and Chief People Officer, sold a total of $274K in open-market sales over a 7-day | Jun 1, 2026 |
| CTXR | 8-K | neutral | 4/10 | Citius Pharmaceuticals' subsidiary Citius Oncology presented Phase 1 data for LYMPHIR in combination with pembrolizumab | Jun 1, 2026 |
| CTOR | 8-K | neutral | 4/10 | Citius Oncology issued a press release highlighting Phase 1 data from an investigator-initiated study of LYMPHIR (denile | Jun 1, 2026 |
| PGEN | CLUSTER | neutral | 3/10 | Four top executives at Precigen (CEO, CFO, COO, CLO) sold a combined $1.02M in open-market sales on May 28, 2026, all at | Jun 1, 2026 |
| PGEN | CLUSTER | neutral | 3/10 | Three top executives at Precigen (CEO, COO, CLO) sold a combined $833K in open-market sales on May 28, 2026, at $4.36/sh | Jun 1, 2026 |
| JAZZ | 144 | neutral | 3/10 | Bruce C. Cozadd, Chairman and CEO of Jazz Pharmaceuticals, filed a Form 144 on June 1, 2026, indicating intent to sell 6 | Jun 1, 2026 |
| GLUE | CLUSTER | neutral | 3/10 | Two C-suite insiders at Monte Rosa Therapeutics sold a combined $163K in open-market sales within a week, with the CSO e | Jun 1, 2026 |
| MIRM | 144 | neutral | 2/10 | Director Saira Ramasastry filed a Form 144 notice of intent to sell 3,977 shares of Mirum Pharmaceuticals common stock, | Jun 1, 2026 |
| ATYR | 8-K | neutral | 4/10 | aTyr Pharma filed an 8-K with an investor presentation detailing plans for a new Phase 3 study (C-006) of efzofitimod in | Jun 1, 2026 |
| TWST | CLUSTER | neutral | 3/10 | A cluster of insider selling at Twist Bioscience over the past week, led by CEO Emily Leproust who sold ~$3.2M in open-m | Jun 1, 2026 |
| SYRE | 8-K | bullish | 7/10 | Spyre Therapeutics expanded its license agreement with Paragon Therapeutics, removing the previous restriction that limi | Jun 1, 2026 |
| ORKA | 8-K | bullish | 7/10 | Oruka Therapeutics amended its IL-23 license agreement with Paragon Therapeutics to expand the field of use to include i | Jun 1, 2026 |
| XCUR | PRESS-RELEASE | neutral | 4/10 | Exicure received a Nasdaq non-compliance notice for late filing of its Q1 2026 10-Q, but filed the report on May 29, 202 | Jun 1, 2026 |
| XCUR | 8-K | neutral | 3/10 | Exicure disclosed it received a Nasdaq delinquency notice on May 28, 2026 for late filing of its Q1 2026 10-Q, but filed | Jun 1, 2026 |